|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NPIPB15 |
Gene summary for NPIPB15 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NPIPB15 | Gene ID | 440348 |
| Gene name | nuclear pore complex interacting protein family member B15 | |
| Gene Alias | A-761H5.4 | |
| Cytomap | 16q23.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A6NHN6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 440348 | NPIPB15 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.65e-03 | -2.26e-01 | -0.1001 |
| 440348 | NPIPB15 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.89e-03 | -2.50e-01 | 0.096 |
| 440348 | NPIPB15 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.32e-02 | -2.22e-01 | 0.0674 |
| 440348 | NPIPB15 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 7.90e-04 | -2.32e-01 | 0.294 |
| 440348 | NPIPB15 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.48e-04 | -2.18e-01 | 0.3859 |
| 440348 | NPIPB15 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.44e-04 | -2.27e-01 | 0.3005 |
| 440348 | NPIPB15 | A015-C-203 | Human | Colorectum | FAP | 2.10e-03 | 1.30e-01 | -0.1294 |
| 440348 | NPIPB15 | A002-C-203 | Human | Colorectum | FAP | 3.57e-03 | 3.68e-01 | 0.2786 |
| 440348 | NPIPB15 | A002-C-021 | Human | Colorectum | FAP | 4.39e-02 | 2.13e-01 | 0.1171 |
| 440348 | NPIPB15 | A002-C-205 | Human | Colorectum | FAP | 2.78e-05 | 2.21e-01 | -0.1236 |
| 440348 | NPIPB15 | A015-C-005 | Human | Colorectum | FAP | 3.28e-06 | 5.22e-01 | -0.0336 |
| 440348 | NPIPB15 | A015-C-106 | Human | Colorectum | FAP | 1.66e-02 | 3.45e-01 | -0.0511 |
| 440348 | NPIPB15 | A002-C-114 | Human | Colorectum | FAP | 3.11e-02 | 1.33e-01 | -0.1561 |
| 440348 | NPIPB15 | A015-C-104 | Human | Colorectum | FAP | 6.26e-05 | 1.93e-01 | -0.1899 |
| 440348 | NPIPB15 | A015-C-202 | Human | Colorectum | FAP | 1.67e-12 | 5.08e-01 | -0.0849 |
| 440348 | NPIPB15 | A002-C-016 | Human | Colorectum | FAP | 1.06e-03 | 1.77e-01 | 0.0521 |
| 440348 | NPIPB15 | A001-C-203 | Human | Colorectum | FAP | 1.90e-04 | -2.02e-01 | -0.0481 |
| 440348 | NPIPB15 | A002-C-116 | Human | Colorectum | FAP | 3.74e-05 | -8.31e-02 | -0.0452 |
| 440348 | NPIPB15 | A008-E-015 | Human | Colorectum | FAP | 1.49e-03 | 3.48e-01 | 0.0177 |
| 440348 | NPIPB15 | A014-C-008 | Human | Colorectum | FAP | 7.77e-05 | 3.22e-01 | -0.191 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NPIPB15 | SNV | Missense_Mutation | novel | c.398G>A | p.Arg133Gln | p.R133Q | A6NHN6 | protein_coding | tolerated_low_confidence(0.4) | benign(0.374) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NPIPB15 | SNV | Missense_Mutation | novel | c.1304A>G | p.Asn435Ser | p.N435S | A6NHN6 | protein_coding | deleterious_low_confidence(0.03) | benign(0.053) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NPIPB15 | SNV | Missense_Mutation | novel | c.298N>C | p.Ser100Pro | p.S100P | A6NHN6 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-AR-A24N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NPIPB15 | SNV | Missense_Mutation | rs780007640 | c.1180G>A | p.Ala394Thr | p.A394T | A6NHN6 | protein_coding | tolerated_low_confidence(0.15) | benign(0.001) | TCGA-D8-A27M-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | methotrexate+5 | SD |
| NPIPB15 | SNV | Missense_Mutation | rs780007640 | c.1180N>A | p.Ala394Thr | p.A394T | A6NHN6 | protein_coding | tolerated_low_confidence(0.15) | benign(0.001) | TCGA-D8-A27R-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin+cyclophosphamide | SD |
| NPIPB15 | SNV | Missense_Mutation | novel | c.928N>T | p.Pro310Ser | p.P310S | A6NHN6 | protein_coding | tolerated_low_confidence(0.05) | possibly_damaging(0.714) | TCGA-EW-A3E8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| NPIPB15 | SNV | Missense_Mutation | novel | c.148N>G | p.Lys50Glu | p.K50E | A6NHN6 | protein_coding | tolerated_low_confidence(0.15) | possibly_damaging(0.631) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| NPIPB15 | SNV | Missense_Mutation | novel | c.568N>C | p.Glu190Gln | p.E190Q | A6NHN6 | protein_coding | tolerated_low_confidence(0.06) | probably_damaging(0.966) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| NPIPB15 | SNV | Missense_Mutation | novel | c.1004N>T | p.Ser335Leu | p.S335L | A6NHN6 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.899) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| NPIPB15 | SNV | Missense_Mutation | rs759133354 | c.1253N>T | p.Ala418Val | p.A418V | A6NHN6 | protein_coding | deleterious_low_confidence(0) | benign(0.337) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |